Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dotinurad PK/PD and DDI with Allopurinol in Gout and Hyperuricemia
NCT06056570Phase 2Completed
- Sponsor
- Urica Therapeutics
- Start
- Oct 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dotinurad in gout, hyperuricemia, sponsored by Urica Therapeutics. Started Oct 2023; status: completed.
02
Drugs
dotinurad
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT06056570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06056570.